Bristol Myers Squibb Wins FDA Accelerated Approval for First CELMoD Therapy Zenbexus

Bristol Myers Squibb has received accelerated approval from the U.S. Food and Drug Administration for its novel CELMoD therapy, Zenbexus (iberdomide), in combination with daratumumab, hyaluronidase‑fihj and dexamethasone (ZDd) for adult patients with relapsed or refractory multiple myeloma who have undergone at least one prior therapy including a proteasome inhibitor and an immunomodulatory agent.

This approval, granted on August 13, 2026, marks the first FDA clearance for a CELMoD — a cereblon-modulating protein degrader — and is based on findings from the Phase 3 EXCALIBER‑RRMM trial, which demonstrated a statistically significant improvement in minimal residual disease‑negative complete response rates: 41% for the ZDd regimen versus 21% for the daratumumab, bortezomib and dexamethasone combo (p < 0.0001).

The FDA’s decision is rooted in MRD‑negative CR as a surrogate endpoint — a novel regulatory benchmark in multiple myeloma that may accelerate future trial designs. Full confirmation of clinical benefit will depend on ongoing confirmatory trials.

Why It Matters

Zenbexus is the first approved CELMoD therapy, representing a transformative advance in targeted protein degradation. Approval based on MRD‑negative CR signals a regulatory evolution where deep response can catalyze accelerated approvals, potentially hastening drug development timelines.

The approval underscores the strength of BMS’s CELMoD platform as a core pillar in its oncology pipeline, reinforcing investor confidence in its innovation trajectory.

What’s Next

Bristol Myers Squibb continues to have another CELMoD candidate — mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) — under FDA review, with a PDUFA target action date of May 13, 2027.

Looking ahead, Zenbexus must demonstrate durable clinical benefit in confirmatory trials to maintain this accelerated approval. Success in those studies could solidify CELMoDs as foundational therapies in multiple myeloma care.

Implications for BMY Investors

This approval offers a fresh growth catalyst for Bristol Myers Squibb, potentially driving adoption of a new drug class while reinforcing its R&D leadership. With Zenbexus now on the market and mezigdomide advancing through regulatory review, BMY stands well-positioned to deliver near- and medium-term value.

The company’s stock price of $62.62 as of September 21, 2026 (down 0.74%) reflects its broader market context; while new approvals may not immediately translate into share gains, they contribute to long-term investor sentiment.

Investors will monitor uptake trajectories for Zenbexus, updates from the confirmatory trial, and progress toward potential approval of mezigdomide next year.